Stay updated on Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial
Sign up to get notified when there's something new on the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page.

Latest updates to the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe page shows a new revision tag, v3.5.4, replacing the previous v3.5.3, indicating a small update to the document version. The change affects metadata only and does not modify study details or results.SummaryDifference0.1%

- Check26 days agoNo Change Detected
- Check40 days agoChange DetectedThe page’s site “Revision” indicator was updated from v3.5.2 to v3.5.3.SummaryDifference0.1%

- Check47 days agoChange DetectedRevision upgraded from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check76 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0; no substantive study information changes are evident.SummaryDifference0.1%

- Check83 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check112 days agoChange DetectedAdded Primary peritoneal carcinoma as a study condition and added the Genetic and Rare Diseases Information Center as a resource. Removed the government funding lapse notice and updated the page revision to v3.4.2.SummaryDifference0.6%

Stay in the know with updates to Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page.